E-drug: Cost effectiveness in Drug Registration (cont'd)
-------------------------------------------------------------------------
Dear Chinta and other E-drug colleagues,
Australia does not use economic evaluation for drug registration
procedures (only safety and efficacy considerations) but we do use
economic evaluation to determine if a new drug (or a new indication
for an old one) should be added to our national essential drug list
(our Pharmaceutical Benefits Scheme) and thus receive government
subsidy.
Australian guidelines (including economic analyses requirements) for
pharmaceutical industry submissions to our Pharmaceutical Benefits
Advisory Committee, can be found at:
http://www.health.gov.au/haf/docs/pharmpac/gusubpac.htm.
Further information may be obtained from the Pharmaceutical
Evaluation Section within the Pharmaceutical Benefits Branch of our
Commonwealth Department of Health. Contact Peter McManus
(tel: 61 2 6289 7293; e-mail: peter.mcmanus@health.gov.au) or
Andrew Mitchell, Director of the PES, (tel: 61 2 6289 7486;
e-mail: andrew.mitchell@health.gov.au).
Australian requirements for economic evaluation of pharmaceuticals
have caused considerable controversy; see:
http://www-sph.health.latrobe.edu.au/PBAC/.
Cheers,
Ken
Dr. Ken Harvey
Senior Lecturer, School of Public Health
Room 221, Building HS1 (NW9)
La Trobe University, Bundoora, 3086, Australia
Tel: +61 3 9479 5773
Fax: +61 3 9479 1783
Personal mobile 0419 181910
http://www-sph.health.latrobe.edu.au/kharvey/
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Information and archive http://www.healthnet.org/programs/edrug.html
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.